Australian Clinical Labs Ltd Asset Resilience Ratio
Australian Clinical Labs Ltd asset resilience ratio. Australian Clinical Labs Ltd (ACL) has an Asset Resilience Ratio of 4.11% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Australian Clinical Labs Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Australian Clinical Labs Ltd (2016–2025)
Asset resilience ratio of Australian Clinical Labs Ltd from 2016 to 2025. This chart shows how Australian Clinical Labs Ltd's Asset Resilience Ratio has changed over time. Read ACL liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Australian Clinical Labs Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACL current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$22.43 Million | 3.99% |
| Short-term Investments | AU$703.00K | 0.12% |
| Total Liquid Assets | AU$23.14 Million | 4.11% |
Asset Resilience Insights
- Limited Liquidity: Australian Clinical Labs Ltd maintains only 4.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Australian Clinical Labs Ltd Industry Peers by Asset Resilience Ratio
Compare Australian Clinical Labs Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang DiAn Diagnostics Co
SHE:300244 |
Diagnostics & Research | 3.61% |
|
Shanghai Runda Med Tech Co
SHG:603108 |
Diagnostics & Research | 0.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Lumibird SA
PA:LBIRD |
Diagnostics & Research | 22.85% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 1.71% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
Australian Clinical Labs Ltd Asset Resilience Ratio by Year (2016–2025)
Australian Clinical Labs Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Australian Clinical Labs Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 3.85% | AU$22.12 Million ≈ $15.65 Million |
AU$574.84 Million ≈ $406.73 Million |
0.00pp |
| 2024-12-31 | 3.85% | AU$22.12 Million ≈ $15.65 Million |
AU$574.84 Million ≈ $406.73 Million |
-0.68pp |
| 2024-06-30 | 4.53% | AU$26.84 Million ≈ $18.99 Million |
AU$593.06 Million ≈ $419.63 Million |
0.00pp |
| 2023-12-31 | 4.53% | AU$26.84 Million ≈ $18.99 Million |
AU$593.06 Million ≈ $419.63 Million |
+0.97pp |
| 2023-06-30 | 3.56% | AU$20.59 Million ≈ $14.57 Million |
AU$578.91 Million ≈ $409.62 Million |
0.00pp |
| 2022-12-31 | 3.56% | AU$20.59 Million ≈ $14.57 Million |
AU$578.91 Million ≈ $409.62 Million |
+3.38pp |
| 2022-06-30 | 0.18% | AU$1.13 Million ≈ $802.38K |
AU$628.04 Million ≈ $444.38 Million |
-4.20pp |
| 2021-12-31 | 4.38% | AU$27.51 Million ≈ $19.46 Million |
AU$628.04 Million ≈ $444.38 Million |
+4.16pp |
| 2021-06-30 | 0.22% | AU$1.05 Million ≈ $742.23K |
AU$474.70 Million ≈ $335.88 Million |
-7.42pp |
| 2020-12-31 | 7.64% | AU$36.28 Million ≈ $25.67 Million |
AU$474.70 Million ≈ $335.88 Million |
+7.52pp |
| 2020-06-30 | 0.12% | AU$435.00K ≈ $307.79K |
AU$366.05 Million ≈ $259.01 Million |
-9.52pp |
| 2019-12-31 | 9.64% | AU$35.28 Million ≈ $24.97 Million |
AU$366.05 Million ≈ $259.01 Million |
+8.99pp |
| 2019-06-30 | 0.65% | AU$1.00 Million ≈ $708.27K |
AU$153.61 Million ≈ $108.69 Million |
-2.69pp |
| 2018-12-31 | 3.34% | AU$5.13 Million ≈ $3.63 Million |
AU$153.61 Million ≈ $108.69 Million |
+0.89pp |
| 2018-06-30 | 2.45% | AU$2.91 Million ≈ $2.06 Million |
AU$119.06 Million ≈ $84.24 Million |
-5.77pp |
| 2017-12-31 | 8.22% | AU$9.78 Million ≈ $6.92 Million |
AU$119.06 Million ≈ $84.24 Million |
+7.97pp |
| 2017-06-30 | 0.25% | AU$301.00K ≈ $212.98K |
AU$120.89 Million ≈ $85.54 Million |
-5.82pp |
| 2016-12-31 | 6.07% | AU$7.34 Million ≈ $5.19 Million |
AU$120.89 Million ≈ $85.54 Million |
-- |
About Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veter… Read more